Abstract
AbstractAn exceptional effort by the scientific community has led to the development of multiple vaccines against COVID-19. Efficacy estimates for these vaccines have been widely communicated to the general public, but are nonetheless challenging to compare because they are based on phase 3 trials that differ in study design, definition of vaccine efficacy and in the handling of cases arising shortly after vaccination. In this work, we investigate the impact of these choices on vaccine efficacy estimates, both theoretically and by re-analyzing the Janssen and Pfizer COVID-19 trial data under a uniform protocol. We moreover study the causal interpretation that can be assigned to per-protocol analyses typically performed in vaccine trials. Finally, we propose alternative estimands to measure the intrinsic vaccine efficacy in settings with delayed immune response.
Publisher
Cold Spring Harbor Laboratory
Reference35 articles.
1. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
2. Centers for Disease Control and Prevention (2020). Malaria. https://www.nc.cdc.gov/travel/diseases/malaria.
3. Centers for Disease Control and Prevention (2021). Key facts about seasonal flu vaccine. https://www.cdc.gov/flu/prevent/keyfacts.htm.
4. Regression models and life-tables;Journal of the Royal Statistical Society: Series B (Methodological),1972
5. Dean, N. E. , Gsell, P.-S. , Brookmeyer, R. , De Gruttola, V. , Donnelly, C. A. , Halloran, M. E. , Jasseh, M. , Nason, M. , Riveros, X. , Watson, C. , et al. (2018a). Considerations for the design of vaccine efficacy trials during public health emergencies. bioRxiv, page 261875.